Enhancing First-Line TKI Efficacy in PD-L1-Positive EGFR-Mutated NSCLC: The Role of Antiangiogenic Agents
Preprint in Research Square (January 2024)
The most recent citing publications are shown below. View all 2 publications that cite this research output on Dimensions.
Editorial: Community series in immunotherapy with checkpoint inhibitors for non-small cell lung cancer, colon cancer, and esophageal cancer, volume II
Article in Frontiers in Immunology (July 2023)